USFDA completes inspection at Unit XIV of Aurobindo Pharma

20 May 2023 Evaluate

The United States Food and Drug Administration (USFDA) has completed inspection Aurobindo Pharma’s Unit XIV, an API Non antibiotic Manufacturing facility situated at Paravada Industrial Area, Anakapalli District. Andhra Pradesh, from May 15 to May 19 2023. At the end of the inspection, The company has been issued a 'Form 483' with four observations. The observations are procedural in nature. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1167.20 -5.10 (-0.44%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×